Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6886775 | 0.88 | RAB9A (0.35) | KCNH2 | |
| SCHEMBL6888343 | 0.84 | CHRNA7 (0.40) | KCNH2HTR3A | |
| SCHEMBL6888244 | 0.81 | AADAT (0.35) | KCNH2HTR3A | |
| SCHEMBL6887730 | 0.81 | NPC1 (0.32) | KCNH2 | |
| SCHEMBL6886701 | 0.72 | CHRNA7 (0.41) | KCNH2HTR3A | |
| SCHEMBL6887762 | 0.72 | TNKS2 (0.42) | KCNH2HTR3A | |
| SCHEMBL6887948 | 0.70 | PARG (0.40) | KCNH2HTR3A | |
| SCHEMBL6888036 | 0.70 | CHRNA7 (0.43) | KCNH2HTR3A | |
| SCHEMBL6888107 | 0.69 | L3MBTL1 (0.37) | KCNH2 | |
| SCHEMBL6887450 | 0.69 | CHRNA7 (0.43) | KCNH2HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841289-B2 | Heterocyclic derivatives | MERCK SHARP & DOHME B.V. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841289-B2 | Heterocyclic derivatives | MERCK SHARP & DOHME B.V. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841289-B2 | Heterocyclic derivatives | MERCK SHARP & DOHME B.V. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-08-16 | — | — | US | disclosed |
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-08-16 | — | — | US | disclosed |
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-08-16 | — | — | US | disclosed |
| WO-2011045258-A1 | CONDENSED AZINE - DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR | N.V. ORGANON (NL) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | CHRNA5, CHRM5, CHRNA7 | KCNH2 728/4885HTR3A 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.